Condition: Melanoma Stage III · Melanoma Stage IV · Sponsor: University of California, San Francisco
This phase II trial studies how well binimetinib and imatinib work in treating patients with stage III-IV KIT-mutant melanoma that cannot be removed by surgery (unresectable). Binimetinib and imatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving binimetinib and imatinib may help treat patients with KIT-mutant melanoma.
This description comes directly from the study's public registry record.
Sonia Contreras Martinez · (415) 514-6427 · sonia.contrerasmartinez@ucsf.edu
Always discuss trial participation with your own doctor first.
| UC San Diego Moores Cancer Center | La Jolla, California, United States | Recruiting |
| University of California, San Francisco | San Francisco, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04598009